Back to top
more

Neogen (NEOG)

(Delayed Data from NSDQ)

$14.44 USD

14.44
1,190,769

+0.16 (1.12%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Steris (STE) Q3 Dismal: Earnings Miss Estimates, View Cut

Steris Plc (STE) reported third-quarter fiscal 2017 adjusted earnings per share (EPS) of 98 cents, in line with the year-ago quarter.

    Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates

    Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.

      Cardinal Health (CAH) Q2 Earnings Beat Estimates, Rise Y/Y

      Cardinal Health Inc. (CAH) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.

        Phirbo Animal (PAHC) Tops Q2 Earnings, Reaffirms FY17 View

        Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 39 cents in the second quarter of fiscal 2017.

          QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4

          QIAGEN N.V. (QGEN) reported fourth-quarter 2016 adjusted earnings per share (excluding restructuring expenses) of 39 cents, up 7.7% year over year.

            IDEXX Laboratories (IDXX) Q4 Earnings Rise; Tweaks View

            IDEXX Laboratories Inc. (IDXX) recorded fourth-quarter 2016 earnings per share (EPS) of 58 cents, up 21% year over year on a reported basis.

              Becton, Dickinson (BDX) Beats on Q1 Earnings & Revenues

              Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2017 earnings of $2.33 per share, which beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter.

                Boston Scientific (BSX) Tops Q4 Earnings, Offers 2017 View

                Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 30 cents, up 15.4% from the year-ago adjusted number.

                  Hologic (HOLX) Beats on Q1 Earnings, Lowers '17 Guidance

                  Hologic Inc. (HOLX) reported first-quarter fiscal 2017 adjusted earnings per share (EPS) of 52 cents, up 13% year over year.

                    Edwards Lifesciences (EW) Beats on Earnings & Sales in Q4

                    Edwards Lifesciences Corp. (EW) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%.

                      Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue

                      Accuray Inc. (ARAY) reported a loss of 11 cents per share in the second quarter of fiscal 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents.

                        Align Technology (ALGN) Q4 Earnings and Revenues in Line

                        Align Technology Inc. (ALGN) reported adjusted earnings of 67 cents per share in the fourth quarter of 2016, up 11.6% from 60 cents in the year-ago quarter.

                          Illumina (ILMN) Beats Q4 Earnings & Revenues, Guides 2017

                          Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 85 cents in the fourth quarter of 2016, which exceeded the Zacks Consensus Estimate by 4.9%.

                            Zimmer Biomet (ZBH) Beats on Q4 Earnings, Knees Improve

                            Zimmer Biomet Holdings, Inc. (ZBH) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.14, up 2.4% year over year.

                              AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Lag

                              AmerisourceBergen Corporation (ABC) posted earnings (excluding one-time items) of $1.36 per share in the first quarter of fiscal 2017, beating the Zacks Consensus Estimate of $1.24.

                                Hill-Rom TruSystem 3000 Table Boosts Surgical Solution Suite

                                Hill-Rom Holdings (HRC) recently launched TruSystem 3000 Mobile Operating Table to fulfill hospitals' need to equip operating rooms with quality medical devices at a reasonable cost.

                                  Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat

                                  Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected fourth-quarter and full-year 2016 earnings results.

                                    Hill-Rom (HRC) Q1 Earnings Meet, Revenues Lag Estimates

                                    Hill-Rom Holdings, Inc. (HRC) reported first-quarter fiscal 2017 adjusted earnings per share of 75 cents, up 10.3% from the year-ago quarter.

                                      Abaxis (ABAX) Q3 Bleak: Earnings In Line, Revenues Miss

                                      Abaxis, Inc. (ABAX) - a global provider of point-of-care blood analyzers - reported third-quarter fiscal 2017 earnings per share of 30 cents, in line with the Zacks Consensus Estimate.

                                        Cardiovascular Systems (CSII) Q2 Earnings Better Estimates

                                        Cardiovascular Systems, (CSII) reported earnings per share of 3 cents in second-quarter fiscal 2017, reflecting a massive improvement from the year-ago quarter's loss of 47 cents.

                                          Mead Johnson (MJN) Misses Q4 Earnings, Sales; Guides '17

                                          Mead Johnson (MJN) reported fourth-quarter 2016 adjusted EPS of 78 cents, missing the Zacks Consensus Estimate of 83 cents by 6%.

                                            Quest Diagnostics (DGX) Tops Q4 Earnings, Offers '17 View

                                            Quest Diagnostics' (DGX) fourth-quarter 2016 adjusted earnings per share (EPS) of $1.31 came in 4 cents ahead of the Zacks Consensus Estimate.

                                              PetMed (PETS) Lags Q3 Earnings Estimates, Tops Revenues

                                              PetMed Express (PETS) announced earnings per share (EPS) of 24 cents for the third quarter of fiscal 2017.

                                                Abbott Labs (ABT) Tops Q4 Earnings Estimates, Sales In Line

                                                Abbott Laboratories (ABT) reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate.

                                                  ResMed (RMD) Beats Earnings and Revenue Estimates in Q2

                                                  ResMed Inc. (RMD) announced second-quarter fiscal 2017 adjusted earnings per share (EPS) of 73 cents, consistent with the prior-year quarter level.